---
title: 'Engineering the best transplant outcome for high-risk acute myeloid leukemia:
  the donor, the graft and beyond'
date: '2023-12-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38054912/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20231207170721&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Allogeneic hemopoietic cell transplantation remains the goal of therapy
  for high-risk acute myeloid leukemia (AML). However, treatment failure in the form
  of leukemia relapse or severe graft-versus-host disease remains a critical area
  of unmet need. Recently, significant progress has been made in the cell therapy-based
  interventions both before and after transplant. In this review, the Stem Cell Engineering
  Committee of the International Society for Cell and Gene Therapy summarizes ...
disable_comments: true
---
Allogeneic hemopoietic cell transplantation remains the goal of therapy for high-risk acute myeloid leukemia (AML). However, treatment failure in the form of leukemia relapse or severe graft-versus-host disease remains a critical area of unmet need. Recently, significant progress has been made in the cell therapy-based interventions both before and after transplant. In this review, the Stem Cell Engineering Committee of the International Society for Cell and Gene Therapy summarizes ...